Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 12, 2014, Pages 3649-3658

  Zhao, Guangyu ^a   Miao, Yu ^a   Guo, Yan ^a   Qiu, Hongjie ^a   Sun, Shihui ^a   Kou, Zhihua ^a   Yu, Hong ^a   Li, Junfeng ^a   Chen, Yue ^b   Jiang, Shibo ^c,d   Du, Lanying ^c   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Bacillus subtilis; Influenza virus; M2e; Spores; Surface display

Indexed keywords

BACTERIAL PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; PLACEBO; PROTEIN COTB; PROTEIN COTB M2E3 FUSION PROTEIN; PROTEIN M2; PROTEIN RSM2E3; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; COTB PROTEIN, BACILLUS SUBTILIS; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIVIRAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL SPORE; CELL SURFACE DISPLAY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HETEROLOGOUS EXPRESSION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); INFLUENZA VACCINATION; MOUSE; MOUSE MODEL; MUCOSAL IMMUNITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; PROVOCATION TEST; VIRUS DNA CELL DNA INTERACTION; VIRUS PARTICLE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; FEMALE; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BACILLUS SUBTILIS; BACTERIAL PROTEINS; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SPORES, BACTERIAL; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS;

EID: 84922526966     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.36122     Document Type: Article

References (39)

1. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect 2010; 12:280-6; PMID:20079871; http://dx.doi.org/ 10.1016/j.micinf.2010.01.001
2. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605; PMID:15100303; http://dx.doi.org/10.4049/jimmunol. 172.9.5598
3. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999; 254:138-46; PMID:9927581; http:// dx.doi.org/10.1006/viro.1998.9534
4. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008; 80:168-77; PMID:18598723; http://dx.doi.org/10.1016/j. antiviral.2008.06.002
5. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63; PMID:10502819; http://dx. doi.org/10.1038/13484
6. Kim EH, Park HJ, Han GY, Song MK, Pereboev A, Hong JS, Chang J, Byun YH, Seong BL, Nguyen HH. Intranasal adenovirus vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice. J Virol 2014; 88:9693-703; PMID: 24920793, http://dx.doi.org/ 10.1128/JVI.00823-14
7. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008; 26:201-14; PMID:18063235; http://dx.doi.org/10.1016/j.vaccine. 2007.10.062
8. Ma JH, Yang FR, Yu H, Zhou YJ, Li GX, Huang M, Wen F, Tong G. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge. Virol J 2013; 10:227; PMID:23834899; http://dx.doi.org/10.1186/1743-422X-10-227
9. Wang L, Wang YC, Feng H, Ahmed T, Compans RW, Wang BZ. Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice. Biomed Res Int 2013; 2013:686549; PMID:23984396
10. Mazza P. The use of Bacillus subtilis as an antidiarrhoeal microorganism. Boll Chim Farm 1994; 133:3-18; PMID:8166962
11. Duc le H, Hong HA, Atkins HS, Flick-Smith HC, Durrani Z, Rijpkema S, Titball RW, Cutting SM. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 2007; 25:346-55; PMID:17007969; http://dx.doi. org/10.1016/j.vaccine.2006.07.037
12. Zhou Z, Xia H, Hu X, Huang Y, Ma C, Chen X, Hu F, Xu J, Lu F, Wu Z, et al. Immunogenicity of recombinant Bacillus subtilis spores expressing Clonorchis sinensis tegumental protein. Parasitol Res 2008; 102:293-7; PMID:17924143; http://dx.doi.org/ 10.1007/s00436-007-0762-x
13. Nicholson WL, Munakata N, Horneck G, Melosh HJ, Setlow P. Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments. Microbiol Mol Biol Rev 2000; 64:548-72; PMID:10974126; http://dx.doi.org/10.1128/MMBR. 64.3.548-572.2000
14. Isticato R, Cangiano G, Tran HT, Ciabattini A, Medaglini D, Oggioni MR, De Felice M, Pozzi G, Ricca E. Surface display of recombinant proteins on Bacillus subtilis spores. J Bacteriol 2001; 183:6294-301; PMID:11591673; http://dx.doi.org/10.1128/ JB.183.21.6294-6301.2001
15. Amuguni H, Tzipori S. Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens. Hum Vaccin Immunother 2012; 8:979-86; PMID:22699442; http://dx.doi.org/10.4161/hv.20694
16. Li L, Hu X, Wu Z, Xiong S, Zhou Z, Wang X, Xu J, Lu F, Yu X. Immunogenicity of self-adjuvanticity oral vaccine candidate based on use of Bacillus subtilis spore displaying Schistosoma japonicum 26 KDa GST protein. Parasitol Res 2009; 105:1643-51; PMID:19756753; http://dx.doi.org/10.1007/s00436-009-1606-7
17. Tang Y, Lu J, Wu P, Liu Z, Tian Z, Zha G, Chen H, Wang Q, Wang Q, Hou F, et al. Inactivated vaccine with adjuvants consisting of pattern recognition receptor agonists confers protection against avian influenza viruses in chickens. Vet Microbiol 2014; 172:120-8; PMID:24894132; http://dx.doi.org/10.1016/j.vetmic. 2014.05.007
18. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 2013; 12:1085-94; PMID:24024871; http://dx.doi.org/ 10.1586/14760584.2013.824709
19. Chung S, Lim HM, Kim SD. Formulation of stable Bacillus subtilis AH18 against temperature fluctuation with highly heat-resistant endospores and micropore inorganic carriers. Appl Microbiol Biotechnol 2007; 76:217-24; PMID:17479259; http://dx.doi.org/ 10.1007/s00253-007-0992-y
20. Ciabattini A, Parigi R, Isticato R, Oggioni MR, Pozzi G. Oral priming of mice by recombinant spores of Bacillus subtilis. Vaccine 2004; 22:4139-43; PMID:15474704; http://dx.doi.org/10.1016/j.vaccine. 2004.05.001
21. Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011; 42:1-8; PMID:21082230; http://dx.doi.org/ 10.1007/s11262-010-0547-7
22. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8:499-508; PMID:19348565; http://dx.doi.org/ 10.1586/erv.09.6
23. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, Shaw AR, Taylor DN. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010; 5: e14442; PMID:21203437; http://dx.doi.org/10.1371/ journal.pone.0014442
24. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29:5145-52; PMID:21624416; http://dx. doi.org/10.1016/j.vaccine.2011.05.041
25. Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010; 7:9; PMID:20082709; http://dx.doi.org/ 10.1186/1743-422X-7-9
26. Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J 2010; 7:151; PMID:20624292; http://dx.doi.org/10.1186/1743-422X-7-151
27. Zhao G, Du L, Xiao W, Sun S, Lin Y, Chen M, Kou Z, He Y, Lustigman S, Jiang S, et al. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010; 28:7233-40; PMID:20732469; http://dx.doi.org/10.1016/j.vaccine. 2010.08.049
28. Barnes AG, Cerovic V, Hobson PS, Klavinskis LS. Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. Eur J Immunol 2007; 37:1538-47; PMID:17474150; http://dx.doi.org/ 10.1002/eji.200636875
29. Duc le H, Hong HA, Fairweather N, Ricca E, Cutting SM. Bacterial spores as vaccine vehicles. Infect Immun 2003; 71:2810-8; PMID:12704155; http://dx.doi.org/ 10.1128/IAI.71.5.2810-2818.2003
30. Tam NK, Uyen NQ, Hong HA, Duc le H, Hoa TT, Serra CR, Henriques AO, Cutting SM. The intestinal life cycle of Bacillus subtilis and close relatives. J Bacteriol 2006; 188:2692-700; PMID:16547057; http://dx. doi.org/10.1128/JB.188.7.2692-2700.2006
31. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011; 239:125-48; PMID:21198669; http://dx.doi.org/ 10.1111/j.1600-065X.2010.00970.x
32. Youngman P, Perkins JB, Losick R. Construction of a cloning site near one end of Tn917 into which foreign DNA may be inserted without affecting transposition in Bacillus subtilis or expression of the transposon-borne erm gene. Plasmid 1984; 12:1-9; PMID:6093169; http://dx.doi.org/ 10.1016/0147-619X(84)90061-1
33. Guerout-Fleury AM, Frandsen N, Stragier P. Plasmids for ectopic integration in Bacillus subtilis. Gene 1996; 180:57-61; PMID:8973347; http://dx.doi.org/ 10.1016/S0378-1119(96)00404-0
34. Cutting SM, Vander-Horn PB, editors. Genetic analysis. Chichester, UK: Wiley, c1990. p.27-74. (Harwood CR, Cutting SM, editors. Molecular biological methods for bacillus;)
35. Nicholson WL, Setlow P, editors. Sporulation, germination and outgrowth. Chichester, UK: Wiley, c1990. p.391-450. (Harwood CR, Cutting SM, editors. Molecular biological methods for bacillus;)
36. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28:2731-9; PMID:21546353; http://dx. doi.org/10.1093/molbev/msr121
37. Li Y, Du L, Qiu H, Zhao G, Wang L, Zhou Y, Jiang S, Gao J. A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses. Biosci Trends 2013; 7:129-37; PMID:23836036
38. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32:2100-8; PMID:24560617; http://dx.doi. org/10.1016/j.vaccine.2014.02.004
39. Zhao G, Liu C, Kou Z, Gao T, Pan T, Wu X, Yu H, Guo Y, Zeng Y, Du L, et al. Differences in the pathogenicity and inflammatory responses induced by avian influenza A/H7N9 virus infection in BALB/c and C57BL/6 mouse models. PLoS One 2014; 9:e92987; PMID:24676272; http://dx.doi.org/10.1371/journal. pone.0092987